UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1128-1137

2018

Volltextzugriff (PDF)

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Lung cancer (Amsterdam, Netherlands), 2018-12, Vol.126, p.217-223

2018

Volltextzugriff (PDF)

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Cancers, 2020-08, Vol.12 (9), p.2447

2020

Volltextzugriff (PDF)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Oncoimmunology, 2021-01, Vol.10 (1), p.1865653

2021

Volltextzugriff (PDF)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e001999

2021

Volltextzugriff (PDF)

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

Frontiers in immunology, 2024-02, Vol.15, p.1364473-1364473

2024

Volltextzugriff (PDF)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

Frontiers in oncology, 2021-03, Vol.11, p.603223-603223

2021

Volltextzugriff (PDF)

Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology

Oncology reviews, 2024-05, Vol.18, p.1355256-1355256

2024

Volltextzugriff (PDF)

Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12 , 2447

Cancers, 2022-04, Vol.14 (8), p.1957

2022

Volltextzugriff (PDF)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

Frontiers in oncology, 2022-05, Vol.12, p.874712-874712

2022

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor (EGFR) T790M Testing in EGFR-mutated Non-Small Cell Lung Cancer: A Successful Model of Personalized Cancer Care Beyond Resistance

The Israel Medical Association journal, 2019-06, Vol.21 (6), p.416-418

Moskovitz, Mor

2019

Volltextzugriff (PDF)

1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1356-A1356

2023

Volltextzugriff (PDF)

Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature

Case reports in oncological medicine, 2015-01, Vol.2015, p.341064-5

2015

Volltextzugriff (PDF)

Trastuzumab-related cardiac events in the treatment of early breast cancer

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.1-7

2013

Volltextzugriff (PDF)

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.169-180

2023

Volltextzugriff (PDF)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results

SpringerPlus, 2014-02, Vol.3 (1), p.71-71, Article 71

2014

Volltextzugriff (PDF)

O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer

Annals of oncology, 2023-11, Vol.34, p.S1388-S1388

2023

Volltextzugriff (PDF)

A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3160-TPS3160

2020

Volltextzugriff (PDF)

The association between geriatric assessment, body composition measures, and treatment-related toxicity in elderly cancer patients: A prospective cohort study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.12047-12047

2021

Volltextzugriff (PDF)

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Nature medicine, 2024-07, Vol.30 (7), p.1923-1932

2024

Volltextzugriff (PDF)

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment

Journal of neuro-oncology, 2024-02, Vol.166 (3), p.461-469

2024

Volltextzugriff (PDF)

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence

International journal of cancer, 2021-03, Vol.148 (5), p.1183-1191

2021

Volltextzugriff (PDF)

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

Clinical lung cancer, 2022-03, Vol.23 (2), p.122-134

2022

Volltextzugriff (PDF)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

The oncologist (Dayton, Ohio), 2022-02, Vol.27 (1), p.e76-e84

2022

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(60)
Buchkapitel
(1)

Sprache

Englisch
(60)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Oncology
(24)
Humans
(18)
Female
(11)
Lung Cancer
(11)
Lung Neoplasms - Drug Therapy
(11)
Aged
(10)
Middle Aged
(10)
Male
(9)
Cancer
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Immunotherapy
(7)
Lung Neoplasms - Genetics
(7)
Adult
(6)
Patients
(6)
Retrospective Studies
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Chemotherapy
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology

Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12 , 2447

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

Epidermal Growth Factor Receptor (EGFR) T790M Testing in EGFR-mutated Non-Small Cell Lung Cancer: A Successful Model of Personalized Cancer Care Beyond Resistance

1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer

Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature

Trastuzumab-related cardiac events in the treatment of early breast cancer

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results

O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer

A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors

The association between geriatric assessment, body composition measures, and treatment-related toxicity in elderly cancer patients: A prospective cohort study

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

Suchergebnisse filtern